In a landmark decision poised to significantly reshape the pharmaceutical landscape for diabetes and obesity management, Health Canada has granted…
Read More
Bristol Myers Squibb Bets on Milvexian and Cobenfy to Drive Growth into the 2030s Amidst Patent Expiries
Bristol Myers Squibb (BMS) is strategically positioning itself for sustained growth through the 2030s, with upcoming pivotal Phase III readouts…
Read More
Eliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic Proportions
The pharmaceutical industry is bracing for one of the most significant patent cliff events in its history as Eliquis, the…
Read More
Novo Nordisk sues Hims for GLP-1 patent infringement
The pharmaceutical giant Novo Nordisk has initiated legal proceedings against Hims & Hers Health, Inc., alleging patent infringement related to…
Read More
Novo Nordisk sues Hims for GLP-1 patent infringement
In a significant escalation of an ongoing commercial and regulatory dispute, pharmaceutical giant Novo Nordisk has filed a lawsuit against…
Read More
MSD Acquires Terns Pharmaceuticals for $6.7 Billion in Strategic Move to Bolster Oncology Pipeline Ahead of Keytruda Patent Expiry
In a significant development poised to reshape the competitive landscape of cancer therapeutics, global pharmaceutical giant MSD (known as Merck…
Read More
Wegovy HD Receives FDA Approval Amidst Looming Patent Expiries in Key Markets
The U.S. Food and Drug Administration (FDA) has granted approval for a higher-dose formulation of Novo Nordisk’s blockbuster weight-loss medication,…
Read More
Novo Nordisk Sues Hims for GLP-1 Patent Infringement
In a significant escalation of the ongoing battle over the burgeoning GLP-1 weight-loss drug market, pharmaceutical giant Novo Nordisk has…
Read MoreYOU MAY HAVE MISSED
